New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price

More than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on full list prices, according to a new analysis from Amundsen Consulting, a division of...
Read More
Resources for understanding the dangers of drug importation

Recent proposals to allow drug importation from other countries are dangerous for patients and the U.S. drug supply chain. To better understand how these importation schemes could negatively affect...
Read More
ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

In recent years we have seen remarkable scientific breakthroughs in the discovery of new therapies to treat some of the most challenging diseases faced by patients. These groundbreaking medicines...
Read More
Medicare Monday: A discussion on affordability and access to medicines

In case you missed it, the American Society on Aging held its annual conference last week in Chicago, IL, where Lori Reilly, PhRMA executive vice president of policy, research & membership, spoke...
Read More
17 years (and more) of medical discoveries

Someone asked me recently if donated kidneys last forever. It’s been 17 years and a few days since I received one, which has lasted 17 years longer than I thought it would. That may not be forever,...
Read More
ICYMI: What the experts are saying about importation

Voices throughout the U.S. and Canadian health care systems have raised concerns about proposed large-scale drug importation schemes. Former government officials, pharmacy groups and experts have...
Read More
Guest Post: The importance of a modern FDA in drug discovery

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Medicare Monday: Billing code basics for biologics in Part B

We’ve explored the Centers for Medicare & Medicaid Services’ (CMS) flawed policy for reimbursing biologic and biosimilar products before. Today, we’re exploring how proposals from MedPAC would build...
Read More
How drug importation schemes could increase U.S. law enforcement burdens

In recent weeks, we’ve explored some of the dangers of importation for patients and how medicines purchased online can be fake. But what would importation schemes mean for U.S. law enforcement?
Read More
Medicare Monday: A closer look at Part B spending

Earlier this month, MedPAC discussed Part B drug spending growth but neglected to put this information in the context of overall program spending. Spending on Part B medicines continues to be a small...
Read More
Stakeholders Agree: Modernize the legal framework to support move to value-driven health care

Modernizing certain laws and regulations to support the move to value-driven health care is an important step in moving our health care system forward. As part of PhRMA’s proactive policy solutions,...
Read More
Medicare Monday: New study further confirms increased use of generics after Part D

On Medicare Monday, we’ve talked a lot about how things have changed since 2006 and the implementation of Part D. We’ve looked at how Part D costs less than originally projected, how premiums have...
Read More
Guest Post: Room for optimism in ALS research

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Guest Post: Debra of America on Epidermolysis Bullosa

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Guest Post: A Cure for Ellie on Leukodystrophy-LBSL

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Case Study: How one online pharmacy knowingly endangered U.S. consumers

We recently looked at what actually happens when a patient orders a medicine through an online Canadian pharmacy and how the product delivered may not be what the patient ordered. Today, we’re taking...
Read More
Guest Post: Epilepsy Foundation on rare diseases

Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
How innovative medicines are benefiting countries across the globe

It is important to look at costs across health care systems to fully understand how life-changing medicines are providing a more sustainable path forward. Across the globe, medicines are allowing...
Read More